Beam Therapeutics

Rank#4469

Market Cap2.53B

CountryUnited States

Summary

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

History

Founded in 2017, the company traces its origins to the Broad Institute of the Massachusetts Institute of Technology and Harvard University. Co-founders include David R. Liu and Feng Zhang. Prior to its IPO, the company raised nearly $1 billion in venture capital from investors. In a February 2020 IPO, the company raised $180 million.In January 2022, Pfizer and Beam Therapeutics announced a collaboration to develop therapies for rare diseases using CRISPR.

Mission

To revolutionize genetic medicine through precise and efficient gene editing to deliver meaningful therapies to patients in need.

Vision

To create and commercialize medicines that will fundamentally change the practice of genetic medicine.

References

https://en.wikipedia.org/wiki/Beam_Therapeutics

https://in.investing.com/equities/beam-therapeutics-inc

https://finance.yahoo.com/quote/BEAM/profile?p=BEAM

https://www.crunchbase.com/organization/beam-therapeutics

https://sec.report/CIK/0001745999

https://companiesmarketcap.com/

https://www.beamtx.com